Furthering their connections with Yale University, MedBright AI (MBAI.c MBAIF) has announced CareMEDICA, a Yale University School of Medicine affiliated clinic group, as a beta customer for its AI-driven data and analytics platform, MedMatrix!
MBAI's industry-leading AI-powered data analytics platform, MedMatrix, harnesses the power of AI to evaluate and analyze key aspects of healthcare facilities, including patient needs and resource matching, revenue cycle management, patient demographics, facility geography, and competition.
In doing so, MedMatrix can drastically improve healthcare operations by empowering doctors and operators to enhance clinic revenue by 10% at no additional cost to the clinic, while reducing physician burnout and improving patient satisfaction.
Marking MBAI's second beta customer, CareMEDICA is a leading provider of primary care services for patients throughout Connecticut and the South Florida region. Believing in a more personal approach to healthcare, CareMEDICA's is "leveraging AI as a tool to help improve clinical efficiency" to process data faster as detailed by Fausto Petruzziello, MD, Medical Director of CareMEDICA when commenting about the positive outcomes he expects MedMatrix to provide.
This news comes only a week after MBAI's announced its first beta customer, the Dermatology Institute & Skin Scare Center, a leader in dermatologic services in Southern California, who additionally chose to implement MedMatrix to improve their clinic operations.
Citing artificial intelligence's ability to be "one of the most impactful technology drivers in almost every aspect of our lives", MBAI is strongly positioned with a few rare occurrences for small cap companies including the appointment of two US healthcare experts to its Board of Directors, including a Professor of Medicine at Yale Medical School, as well as their participation in the Ken Sperling Lecture Series, a series of medical economics lectures at Yale University School of Medicine.
These are a substantial few announcements as very little emerging technology companies and small cap companies have such strong connections to Yale as only "companies with credibility, relationships and something important do" are on their radar. Notably, MBAI's Investment Chair, Michael Dalsin, has his own significant relationship with Yale, strengthening this partnership.
Posted on Behalf of MedBright AI Investments Inc.